Purple Biotech narrows Q1 net loss as cancer pipeline progresses

Purple Biotech (NASDAQ:PPBT) reported its financial and operational results for the first quarter of 2026, highlighting clinical milestones within its immunotherapy pipeline and a stabilized bottom line supported by non-operating income.

The Rehovot, Israel-based clinical-stage company posted a narrowed net loss of $0.1 million for the three months ended March 31, 2026.

The financial results were insulated by $2.2 million in net finance income, which balanced out an adjusted operating loss and adjusted net loss of $2.1 million each.

Operational expenditures for the quarter included $1.2 million directed toward research and development (R&D) alongside $1 million in general and administrative (G&A) outlays.

The biotech developer concluded the opening quarter with $6.4 million in cash, cash equivalents, and short-term bank deposits.

Management reiterated that its existing capital reserves provide a sufficient operational runway to fund planned clinical developments and overhead requirements into 2027.

Operationally, the quarter was anchored by new data from the company's CAPTN-3 platform, which utilizes masking technology to selectively activate therapies at tumor sites.

Preclinical evaluations for IM1240, a lead tri-specific antibody targeting the 5T4 tumor-associated antigen, demonstrated consistent anti-tumor activity across all tested, treatment-resistant patient-derived samples.